Stocks Health care ACRV
NASDAQ · Health careAcrivon Therapeutics, Inc. (ACRV)
It posted a net loss of $74.2M. In fiscal 2025 capital spending exceeded operating cash flow by $65.3M. At June 30, 2026 it held $41.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
What Acrivon Therapeutics, Inc. does
Acrivon Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ACRV.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$77.9M | -$2.02 | -$65.3M |
| 2024 | n/a | -$80.6M | -$2.38 | -$68.4M |
| 2023 | n/a | -$60.4M | -$2.74 | -$43.9M |
| 2022 | n/a | -$31.2M | -$7.56 | -$32.3M |
| 2022 | n/a | -$16.2M | -$9.32 | -$14.2M |
Latest SEC filings
What Acrivon Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 12, 2026
- August 12, 2026
- August 12, 2026Quarterly report 10-Q · period to June 30, 2026
- June 17, 2026
- May 22, 2026Additional proxy material DEFA14A
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 13, 2026Quarterly report 10-Q · period to March 31, 2026
- May 13, 2026
- April 30, 2026
Insider trades
What the people running Acrivon Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $31K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 31, 2026 | Levin MichaelaChief Business Officer | Received as pay | 30,000 | - |
| August 25, 2026 | Blume-Jensen PeterPresident and CEO, Director | Sold | 14,036 | $31K |
Questions about ACRV
What does Acrivon Therapeutics, Inc. do?
Acrivon Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ACRV.
Is Acrivon Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $74.2M.
When did Acrivon Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 2, 2026.
Similar companies
Compare ACRV with
Follow ACRV
Get an email when Acrivon Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow ACRV: get an email when it filesWhere the numbers come from
Financial figures are the values Acrivon Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.